JP2010533705A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533705A5
JP2010533705A5 JP2010516648A JP2010516648A JP2010533705A5 JP 2010533705 A5 JP2010533705 A5 JP 2010533705A5 JP 2010516648 A JP2010516648 A JP 2010516648A JP 2010516648 A JP2010516648 A JP 2010516648A JP 2010533705 A5 JP2010533705 A5 JP 2010533705A5
Authority
JP
Japan
Prior art keywords
disease
fragment
cathelicidin
diseases
effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010516648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533705A (ja
Filing date
Publication date
Priority claimed from IL184611A external-priority patent/IL184611A0/en
Priority claimed from IL187627A external-priority patent/IL187627A0/en
Application filed filed Critical
Priority claimed from PCT/IL2008/000977 external-priority patent/WO2009010968A2/en
Publication of JP2010533705A publication Critical patent/JP2010533705A/ja
Publication of JP2010533705A5 publication Critical patent/JP2010533705A5/ja
Pending legal-status Critical Current

Links

JP2010516648A 2007-07-15 2008-07-15 抗菌ペプチドまたはその阻害剤を用いた疾病治療 Pending JP2010533705A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL184611A IL184611A0 (en) 2007-07-15 2007-07-15 Disease treatment via antimicrobial peptides or their inhibitors
IL187627A IL187627A0 (en) 2007-11-26 2007-11-26 Disease treatment via antimicrobial peptides or their inhibitors
PCT/IL2008/000977 WO2009010968A2 (en) 2007-07-15 2008-07-15 Disease treatment via antimicrobial peptides or their inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014157915A Division JP5860937B2 (ja) 2007-07-15 2014-08-01 抗菌ペプチドまたはその阻害剤を用いた疾病治療

Publications (2)

Publication Number Publication Date
JP2010533705A JP2010533705A (ja) 2010-10-28
JP2010533705A5 true JP2010533705A5 (enExample) 2011-08-18

Family

ID=39944436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010516648A Pending JP2010533705A (ja) 2007-07-15 2008-07-15 抗菌ペプチドまたはその阻害剤を用いた疾病治療
JP2014157915A Expired - Fee Related JP5860937B2 (ja) 2007-07-15 2014-08-01 抗菌ペプチドまたはその阻害剤を用いた疾病治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014157915A Expired - Fee Related JP5860937B2 (ja) 2007-07-15 2014-08-01 抗菌ペプチドまたはその阻害剤を用いた疾病治療

Country Status (5)

Country Link
EP (1) EP2200628A2 (enExample)
JP (2) JP2010533705A (enExample)
AU (1) AU2008277257B2 (enExample)
CA (1) CA2696833A1 (enExample)
WO (1) WO2009010968A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1966235A4 (en) * 2005-12-29 2010-01-06 Univ Kansas State ANTIMICROBIAL CATHELICIDINPEPTIDE
US20100292132A1 (en) * 2007-09-11 2010-11-18 Dorian Bevec Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
EP2188015A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of salusin beta alone or in combination with octreotide as a therapeutic agent
WO2011091366A2 (en) * 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130123201A1 (en) * 2010-02-25 2013-05-16 University Of Manitoba Modulation of cytokine-induced chronic inflammatory responses
CA3207425A1 (en) 2014-05-09 2015-11-12 Universiteit Utrecht Holding B.V. New cath2 derivatives
DE202014007548U1 (de) 2014-09-16 2014-12-02 Pegasor Oy Vorrichtung zur Spülung einer Partikelmessvorrichtung
WO2017098474A1 (en) 2015-12-09 2017-06-15 Universidade Do Minho Antimicrobial peptide-loaded hyaluronic acid-based formulations, method of production and uses thereof
CN108570103B (zh) * 2018-04-03 2019-07-30 东北农业大学 一种富含色氨酸抗菌肽wk12及其制备方法和应用
CN111375051A (zh) * 2018-12-29 2020-07-07 江苏吉锐生物技术有限公司 一种多肽在制备预防和治疗人乳头瘤病毒感染制剂的应用
EP3943947A1 (en) * 2020-07-22 2022-01-26 Universitat Autònoma de Barcelona Inhibitors of alpha-synuclein aggregation and uses thereof
KR102475936B1 (ko) * 2020-10-15 2022-12-09 코스맥스 주식회사 펩타이드 ll-37을 발현하는 효모를 포함하는 화장료 조성물
CN114533851B (zh) * 2022-03-17 2024-09-24 南京映海月生物科技有限公司 一种多肽Cbf-14在制备镇痛药物中的应用
WO2025210108A1 (en) * 2024-04-03 2025-10-09 Orocidin A/S Composition for treatment of periodontal disease and related method

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
GB1585061A (en) 1977-03-15 1981-02-25 Nat Res Dev Synthesis of peptides
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (en) 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US20030120037A1 (en) 1999-09-22 2003-06-26 Ji Ming Wang Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
CA2383172A1 (en) 1999-09-22 2001-03-29 The Government Of The United States Of America Utilization of fprl1 as a functional receptor by serum amyloid a (saa)
US20020164685A1 (en) 2000-01-31 2002-11-07 Rosen Craig A. Nucleic acids, proteins, and antibodies
DE10029167B8 (de) 2000-06-19 2015-07-02 Leica Microsystems Cms Gmbh Verfahren und Vorrichtung zur Temperaturstabilisierung optischer Bauteile
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
US6610472B1 (en) 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
JP2002288642A (ja) 2001-03-27 2002-10-04 Nec Corp 掌紋部位分割装置とその掌紋部位分割方法、及び掌紋部位分割プログラム
US6839808B2 (en) 2001-07-06 2005-01-04 Juniper Networks, Inc. Processing cluster having multiple compute engines and shared tier one caches
NZ540506A (en) * 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
CN1878789A (zh) * 2003-10-21 2006-12-13 加利福尼亚大学董事会 人凯萨林菌素抗微生物肽

Similar Documents

Publication Publication Date Title
JP2010533705A5 (enExample)
US7183381B2 (en) Composition of lactoferrin related peptides and uses thereof
RU2470016C2 (ru) Производное бипиразола
US10238636B2 (en) Methods of treating liver disease
JP2011528333A5 (enExample)
JP2010031018A5 (enExample)
JP2009544585A5 (enExample)
JP2011225596A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
WO2011094337A8 (en) Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
NZ602824A (en) Sparc binding peptides and uses thereof
JP2014530220A5 (enExample)
JP2010526153A5 (enExample)
JP2009519949A5 (enExample)
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
RU2012136530A (ru) Новые соединения, влияющие на пищевое поведение
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
Irwin et al. Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes
JP2014508758A5 (enExample)
JP2015508765A5 (enExample)
JP2026506026A (ja) 新規多機能オリゴペプチド
US20160002295A1 (en) Methods and compositions for the treatment of bone remodeling disorders
Ganesh et al. Pharmacotherapies to prevent epidural fibrosis after laminectomy: a systematic review of in vitro and in vivo animal models
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application